论文部分内容阅读
作者对欧洲急性缺血性卒中研究合作组(ECASS),采用rTPA静脉溶栓治疗的资料做了分析,旨在探讨不同类型出血性转变(HT)的可能因素。 该组病例涉及14个国家620例病人,凡收缩压>26.7kPa或舒张压>14.7kPa不得入选,全组均在发病6小时内开始治疗,rTPA剂量为1.1mg/kg,治疗的头24小时禁止使用全量肝素及抗血小板剂。在治疗前24±12小时及治疗后6～8小时各做CT检查,620例中有
The authors analyzed data from the European Cooperative Group for Acute Ischemic Stroke (ECASS) using intravenous thrombolysis with rTPA to explore the possible causes of different types of hemorrhagic transformation (HT). This group of patients involved in 620 cases in 14 countries, where systolic blood pressure> 26.7kPa or diastolic blood pressure> 14.7kPa were not eligible, the whole group were started within 6 hours of onset of treatment, rTPA dose of 1.1mg / kg, the first 24 hours of treatment Do not use the full amount of heparin and antiplatelet agents. 24 ± 12 hours before treatment and 6 ~ 8 hours after treatment, each done CT examination, 620 cases were